摘要
肾性贫血是慢性肾脏病(CKD)常见的并发症,近年来,低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHIs)已被开发作为肾性贫血的新型口服治疗药物。血管钙化是CKD患者心血管事件发病率和病死率增加的主要危险因素,研究表明HIF-PHIs有促进血管钙化的可能,因此充分了解HIF-PHIs潜在的危害性并加以重视非常重要。该文就HIF-PHIs在血管钙化中的作用进行综述,为临床治疗提供思路。
Renal anemia is a common complication of chronic kidney disease(CKD).In recent years,hypoxia inducible factor prolyl hydroxylase inhibitor(HIF-PHIs)has been developed and become a new oral drug for the treatment of renal anemia.Vascular calcification is the main risk factor for the increase of incidence rate and mortality of CKD patients.The study shows that HIF-PHIs has the potential to promote vascular calcification.Therefore,it is important to fully understand the potential hazards of HIF-PHIs and overcome them.This paper discusses the role of hif-phis in vascular calcification,in order to summarize its research progress and provide ideas for clinical treatment.
作者
项周霞
戎殳
Xiang Zhou-xia;Rong Shu(Department of Nephrology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China)
出处
《中国现代医学杂志》
CAS
北大核心
2023年第9期64-70,共7页
China Journal of Modern Medicine
基金
国家自然科学基金(No:81970636)。
关键词
肾性贫血
血管钙化
低氧诱导因子脯氨酰羟化酶抑制剂
renal anemia
vascular calcification
hypoxia inducible factor proline hydroxylase inhibitors
作者简介
通信作者:戎殳,E-mail:jingweisy@126.com,Tel:13681811669。
